ADVANCED STOPPER SOLUTION

PremiumCoat®: Proven Compatibility With Current Vial Standards

By: Sebastien Cordier, Bruno Morchain, and Estelle Verger

INTRODUCTION

Whether in the development of new drug products and generics or when repurposing existing drugs, the importance of packaging should never be underestimated. An understanding of the materials involved and an awareness of their compatibility is essential to achieve a secure, hospitable environment that protects a drug until it needs to be used.


The primary container, which is in direct contact with the drug product, plays a critical role in preserving the drug's integrity from the initial point of production through to packaging, distribution, short- or long-term storage, and the moment at which it is administered. Any failure associated with the primary container has the potential to result in serious adverse effects for the patient or

The red arrows point out the blowback.

the healthcare practitioner, which, aside from the human impact, can have significant financial implications for the drug manufacturer.

One of the key functions of the primary container is to maintain closure integrity during the whole life cycle of a drug product. In the case of glass vials - the most common type of primary container for injectable drugs - a key requirement in achieving this closure integrity is the need for seamless compatibility between the glass vial and the rubber stopper.

Even though the dimensions of vials are standardized (ISO8362-1 for manufactured from glass cane and ISO8362-4 for molded glass vials), compatibility issues can still arise, resulting in excessive insertion forces, stoppers accidentally popping off prior to crimping, or container closure integrity being com-




promised. This can lead to significant operational difficulties and even present a risk to patient safety. Selecting the right stopper/vial combination, therefore, is an important choice that can impact both the development of the drug's packaging as well as the filling and finishing operations.


Aptar Pharma's expertise in this area has been developed over 50 years of collaboration with pharma and biotech partners, during which time it has addressed challenges with vaccines, biotech drugs, and small molecules. PremiumCoat®, one of Aptar Pharma's proprietary innovations, combines state-of-the art elastomer formulation with market-proven film-coating technology to create a highly advanced stopper solution. PremiumCoat's unique design has been extensively tested in conjunction with a leading glass supplier to demonstrate compatibility with standard ISO vial designs. For our pharma partners, PremiumCoat can be relied upon to deliver swift packaging validation and regulatory approval.

PREMIUMCOAT: MINIMIZING INSERTION FORCE

The ability to carefully control insertion force is a key factor in promoting operational efficiency and consistency. This is directly dependent on a number of variables, including the dimension of the stopper and vial, the design of the stopper's skirt as well as the hardness of the elastomer. If these parameters are not optimized, the stopper may become difficult to insert, which may hinder the filling line efficacy, or too loosely inserted, which may lead to the stopper accidentally popping off before the crimping stage.

Aptar Pharma's expert team assessed the insertion force of PremiumCoat stop-





A: Representation of the experimental set-up and forces involved in stopper insertion. B: Required insertion force of 20 mm PremiumCoat stopper on European blowback (EBB), American Blowback (ABB), and non-blowback (NBB) vial designs. The data were collected after 24-month aging.


pers on three ISO8362 standard vial neck designs (European blowback, American blowback, and non-blowback, Figure 1) after gamma ray or steam sterilization and after 24 months of aging, which corresponds to the product's shelf-life. The insertion force was measured with a dynamometer while inserting the stopper at a rate of 100 mm/min. The results of the average insertion force (across the aging

period) are summarized in Figure 2.

The test results show that, for each design, the sterilization method does not significantly affect the insertion force (Figure 2), with European blowback and American blowback showing similar insertion forces. While the insertion force reguired for the non-blowback vial is higher, it remains largely within the operational capabilities of standard filling line machinery. These results confirm that the design of Aptar Pharma's PremiumCoat stopper allows for easy insertion into standard vials and that the sterilization method does not impact the insertion force required. PremiumCoat stoppers can, therefore, contribute to optimizing operational efficiency and can be sterilized with either steam or gamma methods, without impacting machinability.

PREMIUMCOAT: LIMITING THE RISK OF POP-OFF OCCURRENCES

Once the stopper is inserted into the vial's neck, a number of forces are at work to determine whether it will maintain its position. On the one hand, the insertion of the stopper causes a pressure to build up in the headspace, thus generating a force that pushes the stopper out of the vial's neck. On the other hand, the friction between the glass and the rubber works to hold the stopper in place. Depending on the glass neck and stopper's design, compression of the rubber against the glass may secure the stopper on the neck or push it out. If the forces that maintain the stopper in the neck are too weak (for example, when friction is reduced by the excessive adjunction of silicon), the stopper is dislodged from the vial's neck – an event called "pop-off" - that inevitably leads to the loss of the drug dose on the filling line.



A: Representation of the forces involved in pop-off mechanism and of the experimental set-up. B: Number of PremiumCoat 20 mm stopper pop-off events observed when placed on European blowback (EBB), American blowback (ABB), and non-blowback (NBB) vial designs. The experiment was performed in a vacuum chamber at 0,2 and 0,4 bar of vacuum with a sample size of n=60.

The only way to avoid pop-off issues is to test the compatibility of the vial with the stopper. Packaging companies, seeking to further limit the risk of pop-off, have also developed specific "blowback" designs for vials and stoppers. The blowback forms a protuberance and/or notch in the neck of the vial (Figure 1) against which the stopper pushes, generating a mechanical force working against pop-off. While specific stopper designs have been developed to work exclusively with blowback vials, non-specific designs can offer similar levels of performance and work equally well with both standard and blowback

via**l**s.

Aptar Pharma's technical teams evaluated how the shape of the PremiumCoat film-coated stopper contributes to reducing the risk of pop-off when used with three standard vial designs. The assessment compared the impact of gamma ray and steam sterilization, with data collected after 24 months of aging. Because no pop-off could be observed in normal conditions (atmospheric pressure), the experimental setting simulated a worst-case scenario by gradually inducing a pressure difference that would favor pop-off events. The results are shown in Figure 3.


The results shown in Figure 3 indicate that at 0.2 bar of vacuum outside the vial, which already represents an abnormal scenario because the pressure difference is pushing the cap out of the vial's neck, no pop-off event was observed regardless of the sterilization method. When the vacuum is further increased, the steam-sterilized stoppers did not suffer from pop-off. For the gamma-sterilized stoppers, only one pop-off was observed for the blowback vial designs and none for the non-blowback design.


These results demonstrate that, even in sub-optimal conditions in which a depression is working toward increasing the risk of pop-off, Aptar Pharma's Premium-Coat stoppers remained tightly secured on the neck of the vials. As such, regardless of the sterilization method used or the vial's design, PremiumCoat stoppers would maintain the integrity of the drug product on filling lines.

PREMIUMCOAT: MAINTAINING CONTAINER CLOSURE INTEGRITY OVER TIME

Once inserted into the neck of the vial and secured in place with aluminium crimping, the stopper plays a key role in ensuring the container remains tightly closed and preventing any exchanges with the outside environment. This container closure integrity is essential for the conservation of the drug and preventing contamination thus, ensuring patient safety.

Aptar Pharma experts evaluated the ability of PremiumCoat stoppers to maintain container closure integrity. The three different vial designs were stoppered under partial vacuum, and the inner pressure of the vial was measured for up to 1 year to monitor the increase. Though this





A: Representation of the experimental set-up. The data were collected using near infrared spectroscopy to measure the pressure and moisture within the headspace of the vial. B: Evaluating the container closure integrity with PremiumCoat 20 mm stoppers inserted in European blowback, American blowback, and non-blowback vials. The data are represented as the average increase of pressure within the vial after one year for stoppers placed on each vial's design. The stoppers are sterilized by steam or gamma ray methods. The Y-axis scale represents the total pressure difference (675 Torr) between the outside (760 Torr) and inside (85 Torr) of the vial.

Orug Development & Delivery September 2021 Vol 21 No 6

strategy represents an extreme case compared with a situation in which the vial's inner pressure is closer to atmospheric pressure, it provides the means to identify any potential defects in container closure integrity. Similar experiments were repeated to evaluate the impact of the sterilization method on container closure integrity.

The results shown in Figure 4 indicate that, even when the stopper has reached the end of its shelf life (2 years of aging) and regardless of the neck design or the sterilization method, the vial pressure increased by less than 10 Torr over 1 year. This differential corresponds to less than 1.5% of the total pressure difference (675 Torr) between the outside (760 Torr) and inside (85 Torr) of the vial, and could be attributed to the natural permeability of Bromobutyl elastomer. Experience tells us that significant leaks result in a fast increase of the inner pressure of the flask (several hundred Torr) within hours or days.

In demonstrating its efficiency at maintaining container closure integrity over the product life cycle and independently of the sterilization method chosen, it can be concluded that Aptar Pharma's PremiumCoat is a proven, versatile solution for enhancing the protection of a drug during storage.

PREMIUMCOAT: DEMONSTRATING COMPATIBILITY WITH STANDARD VIALS

Across these extensive testing strategies, Aptar Pharma's PremiumCoat proved to be compatible with the three main vial standards and the two main sterilization methods. In all situations, PremiumCoat was found to be an efficient and reliable solution for pharma partners by:

- Promoting operational efficiency regardless of vial design or sterilization method
- Protecting the drug on the filling lines by preventing the stopper from popping-off the vial's neck
- Preserving drug product integrity during its storage by maintaining container closure integrity

REFERENCES

Data source: Aptar Pharma internal report, 2020, [#TR20-0204], Villepinte, France

BIOGRAPHIES



Sébastien Cordier is the Technical Product Manager for PremiumCoat projects at Aptar Pharma's Injectables division. A graduate of MINES ParisTech and EDHEC Business School in France, he first spent over 15 years in the automotive industry, where he developed a strong expertise in plastics and elastomers, before joining Aptar Pharma in 2020. In his current role as Technical Product Manager at

Aptar Pharma, he is responsible for the PremiumCoat platform of vial stoppers and syringe plungers, and is dedicated to supporting customer development projects involving coated elastomeric solutions.



Bruno Morchain is Manager of the Technical Center in Villepinte, France, for Aptar Pharma's Injectables division. A graduate in Mechanical Engineering from the University of Technology of Compiègne, he has over 18 years of experience in the pharmaceutical industry. He joined Aptar Pharma in 2012 as a Technical Support Engineer, where he was in charge of supporting customers on elastomeric primary packaging

selection, validation, filing, and use during the product life cycle. In 2018, he became Technical Center Manager, where he leads a technical team involved in developing new products, evaluating their performance and conducting studies to support customers and their projects.



Estelle Verger is the Business
Development Senior Manager for
PremiumCoat-coated solutions for
Aptar Pharma's Injectables division,
and is responsible for the growth of
the PremiumCoat platform in the
global injectable market. A graduate
from ESSEC Business School and
Fachhochschule Dortmund, with a
Masters degree in International
Business Management, she joined
Aptar Pharma in 2011 as a Sales

Manager, Injectables. She then moved to Aptar Pharma's Consumer Healthcare division as a Product Manager, where she was responsible for Airless Dispensing Solutions for pharmaceutical applications for a number of years, before returning to the Aptar Pharma Injectables division in 2020.





Let us help you get there faster, and safely.

Only a few ever reach the summit - those who possess the right combination of intelligence, resilience, bravery, and respect - backed up by a team of experienced and expert partners.

As the challenge to deliver COVID-19 related vaccines and treatments continues, you can count on Aptar Pharma to help you achieve your goal.

Our PremiumCoat® film-coated solutions can help derisk your drug development and support the specific needs of your COVID-19 projects.

PremiumCoat® stoppers, our proven multidose vial containment solution, can reliably accommodate up to 20 piercings, enabling HCPs to vaccinate and treat more people, more efficiently. Our platform approach with PremiumCoat® 1mL long and 1-3mL syringe plungers facilitates your transition to Pre-Filled Syringes to anticipate long term vaccination strategies.

Aptar Pharma. Enabling the rapid deployment of your vaccines worldwide.

To reach the summit faster, and with less risk, contact **Estelle Verger**, Business Development Senior Manager, Aptar Pharma, at estelle.verger@aptar.com

Delivering solutions, shaping the future.



